biolitec AG: biolitec AG: listing of the shares on the Frankfurt Stock Exchange terminated

Vienna (pta020/17.11.2014/14:24 UTC+1) Last trading day of biolitec shares was November 14, 2014 - inadequate financing function - trading of biolitec shares on the Frankfurt Stock Exchange terminated - closing price of 9.90 Euro in Xetra trading

Vienna, November 17, 2014 - The trading of biolitec shares (ISIN AT0000A0VCT2) in the Entry Standard of the Frankfurt stock exchange has been terminated. As published previously, the Board of Directors of biolitec AG had terminated the quotation in a timely manner with the approval of the Supervisory Board. The last trading day in the Entry Standard of the Frankfurt Stock Exchange was November 14, 2014.

According to Dr. Wolfgang Neuberger, CEO of biolitec AG, reasons for the delisting were, amongst others, the persistent illiquidity of the biolitec shares. Due to the low trading volume, a financing function was no longer provided. As the quotation and the associated requirements of the capital market still caused high costs, the decision to terminate the listing and trading on the Frankfurt Stock Exchange was taken.

The biolitec share terminated its quotation in the Entry Standard on Friday with a closing price of 9.90 Euro in the Xetra trading of the Frankfurt Stock Exchange.

About biolitec:
biolitec AG is one of the leading companies worldwide in the field of medical laser treatments and the only provider that possesses all relevant core competencies - photosensitizers, laser devices and optical fibers - in the field of photodynamic therapy (PDT). Besides laser-based treatment of cancer with the drug Foscan®, biolitec AG primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial(TM) (Endo Laser Vein System) is the most often used laser system worldwide for the treatment of varicose veins. In combination with the Ceralas® HPD laser, the innovative contact fiber XCAVATOR(TM) enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. The new LEONARDO® diode laser by biolitec® is the first universally applicable medical laser which features a combination of two wavelengths, 980nm and 1470nm, and is suitable for interdisciplinary use. Gentle laser treatments in the fields of proctology, ENT, gynecology, thoracic surgery as well as pneumology also belong to the business field of biolitec AG. Further information at www.biolitec.com.

(end)

Emitter:	biolitec AG Untere Viaduktgasse 6/Top 9 1030 Wien Austria
Contact Person:	Jörn Gleisner
Phone:	+49 3641 51953-36
E-Mail:	joern.gleisner@biolitec.com
Website:	www.biolitec.at
ISIN(s):	AT0000A0VCT2 (Share)
Stock Exchange(s):	Free Market in Frankfurt (Basic Board)